FDA's Part 15 hearing (docket FDA-2026-N-7542) was built around serious mental illness — the Federal Register notice never mentions chronic pain, and neither does Executive Order 14401. The pain evidence that advocates are pointing at is one uncontrolled single-patient case report (Jevotovsky et al., Clinical Case Reports 2024), a Phase 1 pilot in phantom limb pain with nine randomized participants, an open-label fibromyalgia pilot with five, a cluster headache RCT that missed statistical significance, and a 2026 migraine RCT where psilocybin did not separate from diphenhydramine. The strongest result in the whole field is in mice. No psilocybin pain trial anywhere is in Phase 3, and chronic pain is not a qualifying condition in New Mexico's medical program. The thesis that touch and neuromodulation matter is plausible and under-studied — but FDA's own final guidance pushes sponsors to strip non-drug components out, not to study them.
The short answer
A chronic-pain advocate got two minutes at FDA's September 14, 2026 hearing and made a reasonable argument: pain is missing from the federal psychedelics conversation. That argument is not the same as evidence that psilocybin treats pain, and right now the evidence is thin enough to say so plainly.
On September 14, 2026, FDA held a Part 15 public hearing titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs" — docket FDA-2026-N-7542. Roughly 80 speakers got two minutes each. One of them, Lynn Watkins, a veteran and chronic pain advocate speaking on her own behalf and for the Psychedelics & Pain Association, used hers to argue two things: that pain belongs in a federal conversation FDA has framed almost entirely around serious mental illness, and that the non-drug components of a psilocybin session — touch, neuromodulation, physical therapy — are doing a large share of the therapeutic work.
One caveat before anything else. We could not independently verify the content of that testimony. The only account we found is the Psychedelics Today article that prompted this piece. We did not locate an FDA transcript, official video, or written docket submission. The vivid detail circulating from it — toes moving within 90 minutes of a dose, after nine years — does not appear in any published paper. Treat it as an uncorroborated first-person account, because that is what it is.
The argument still deserves engagement. So does the evidence base under it, which is smaller than the coverage suggests.
What FDA asked for — and what it refused to hear
FDA solicited comment on four topics: provider training and credentialing, patient safety, access, and data standardization. It explicitly excluded scheduling, legalization, and the merits of any particular drug product. Chronic pain is not mentioned anywhere in the notice.
Read the Federal Register notice yourself: https://www.govinfo.gov/content/pkg/FR-2026-07-14/html/2026-14155.htm
FDA said it was not seeking comment on the safety or effectiveness of any particular product, the merits of any pending application, the scheduling status of any substance under the Controlled Substances Act, legalization or decriminalization, state or local access programs, religious or personal non-medical use, or individual enforcement disputes. That is a narrow box, and it was narrow on purpose.
The policy background FDA cites is Executive Order 14401 (April 18, 2026), "Accelerating Medical Treatments for Serious Mental Illness": https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
That order names major depressive disorder, substance use disorder, serious mental illness broadly, and veteran suicide prevention. It directs National Priority Vouchers to breakthrough-designated psychedelics, a Right to Try pathway including ibogaine, at least $50 million through ARPA-H, and DOJ review of Schedule I products that complete Phase 3 "for a serious mental health disorder." Chronic pain appears nowhere in it.
So Watkins' structural complaint is accurate. The federal machinery moving fastest right now was built for psychiatry.
One more detail worth knowing about the hearing itself: per Psychedelic Alpha's account (https://psychedelicalpha.com/news/no-questions-asked-fdas-psychedelics-public-hearing/), the listening panel drawn from FDA, NIDA, VA, SAMHSA and ARPA-H asked no follow-up questions of any speaker. Two minutes, no dialogue. That is what "public comment" often means.
The case report at the center of this is n=1
Jevotovsky et al., Clinical Case Reports 2024 — a single 54-year-old woman with roughly 20 years of CRPS, unblinded, uncontrolled, self-directed, illegal. The authors themselves say causality cannot be established.
The paper: Jevotovsky DS, Chopra H, Wing C, Spotswood CJ, Castellanos J, "Refractory CRPS pain treated with psilocybin: A case report," *Clinical Case Reports* 2024;12(9):e9421 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11392824/
The patient had a 2003 nerve injury, a 2010 CRPS diagnosis, and had failed gabapentin, NSAIDs, multiple antidepressants and antiepileptics, a spinal cord stimulator implanted in 2015 and removed in 2018, and IV ketamine every six to eight weeks until 2022. She took three doses of dried *Psilocybe cubensis* over five days in a rural indoor setting with a certified facilitator, paired with neuromechanics, neurovisual modulation and tactile reprocessing.
Reported outcomes were dramatic: Brief Pain Inventory 4 down to 0–1 out of 10 at one month and sustained at nine, MADRS 41 to 0, HAM-D 22 to 2, CAPS 54 to 3, falls down roughly 75%, no long-term adverse events noted.
Now the authors' own limitations, verbatim: "The generalizability of the findings is limited due to the case report's single-patient nature. Additionally, the lack of blinding and randomization introduces bias and poses a challenge to establishing causality... Large-scale studies with proper blinding, randomization, and control groups are needed."
Two things PsyBear will not skip past. First, the paper states the patient "sought psilocybin treatment independently, without a physician's recommendation," and notes psilocybin is Schedule I. This was an illegal, self-directed acquisition with no described medical supervision, and IV ketamine was stopped only a week and a half before dosing. That is not a template. Second, two of the five authors carry REMAP Therapeutics affiliations in the author block, while the declared conflicts line reads "The author declares no conflicts of interest."
We are not going to reprint the doses. If you want to understand how dose ranges are discussed, that lives at /dosage, and the preparation side lives at /guides/safe-trip.
Every human pain trial, sorted by evidence tier
Four human studies. The largest randomized 18 people. The only one using an active placebo found no separation from diphenhydramine. Nothing is in Phase 3.
Phantom limb pain — randomized, Phase 1 pilot, 9 randomized of 10 enrolled. Dean JG, Hurwitz E, Furnish T, Castellanos J, et al., *The Journal of Pain*, August 7, 2026 (NCT05224336). Single 25 mg psilocybin versus 100 mg niacin. No emergent suicidality, no serious adverse events. The authors' language: weekly pain intensity "showed trends toward reduction (>30%)" at two and four weeks "but these effects may be attributed to the small sample size and functional unblinding." Secondary coverage claiming a 50–75% reduction overstates the paper. https://painresearchforum.org/paper/feasibility-and-tolerability-of-psilocybin-for-phantom-limb-pain
Fibromyalgia — open-label pilot, no control group, n=5. Aday JS et al., *Frontiers in Pain Research* 2025;6:1527783. Two doses two weeks apart plus eight therapy sessions. Large effect sizes at one month (pain severity d=−2.1), four of five participants had post-dose headache, no serious adverse events. The authors list small n, no control, unblinded staff and participants, intensive therapy support and restrictive exclusion criteria as limitations. Funded in part by Tryp Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC11958999/
Cluster headache — RCT, 16 randomized, 14 analyzed. Schindler EAD, Sewell RA, Gottschalk CH, et al., *Headache* 2022. Attack frequency changed +0.03 per week on placebo versus −3.2 per week on psilocybin — not statistically significant. Well tolerated, and effects were uncorrelated with acute psychotropic intensity. https://pubmed.ncbi.nlm.nih.gov/36416492/ (more at /conditions/cluster-headaches)
Migraine — RCT, n=18, and this is the counter-evidence. Schindler EAD, Gottschalk CH, Pittman BP, D'Souza DC, *Headache* 2026. Single-dose psilocybin, a two-dose pulse, or 25 mg diphenhydramine as active placebo. Finding: "similar reductions in migraine frequency" across all three arms. Diphenhydramine partially mimicked psilocybin's subjective effects, which complicated blinding — and which is exactly why active placebos matter. https://pubmed.ncbi.nlm.nih.gov/41459830/
Preclinical — animal, do not inflate. Askey T, Allen-Ross D, Luzyanin D, et al., *Communications Biology* 2026;9:707. In a mouse spared-nerve-injury model, psilocybin at 0.3 and 1 mg/kg reduced neuropathic pain-like behaviour, the effect was blocked by the 5-HT2A antagonist volinanserin, and a single dose potentiated gabapentin weeks later. The authors frame it as preclinical work warranting human investigation. https://www.nature.com/articles/s42003-026-10065-7
That mouse study is, mechanistically, the most convincing thing in the field. That should tell you where the field is.
Ongoing and unfinished: Dana-Farber's Phase 2 feasibility study in opioid-refractory cancer pain (NCT06001749) targets 15 participants and measures feasibility and acceptability, not analgesia. Trials are also running at UCSF and CAMH, with a Yale psilocybin-assisted physical therapy study not yet recruiting. No psilocybin pain trial anywhere is in Phase 3.
Who is making this argument, and the regulatory problem with it
The hook article is published by Psychedelics Today, written by a co-founder of the organization whose representative testified, about a protocol commercialized by that organization's partner company. Meanwhile FDA's final guidance pushes sponsors in the opposite direction.
The Psychedelics & Pain Association describes itself as "a collaboration between Psychedelics Today, and REMAP Therapeutics," co-founded by Court Wing of REMAP and Joe Moore of Psychedelics Today (https://www.psychedelicsandpain.org/about/). The article that generated this news cycle is published by Psychedelics Today, written by Moore, about testimony from a PPA representative, describing a protocol associated with REMAP. None of that makes the testimony false. All of it should be on the table when you read it.
Now the substantive problem. Watkins' thesis is that the non-drug components carry real therapeutic weight. FDA's July 2026 final guidance, "Psychedelic Drugs: Considerations for Clinical Investigations" (docket FDA-2023-D-1987, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations), partly agrees — per King & Spalding's analysis, FDA states that "the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized."
But the incentive FDA created runs the other way: sponsors who demonstrate efficacy *without* mandating psychotherapy may get broader labeling and simpler distribution. The guidance also flags functional unblinding, recommends blinded central raters and expectancy measures, anticipates REMS and driving studies, and requires that euphoria and perceptual distortion be logged as adverse events. https://www.kslaw.com/news-and-insights/fdas-new-psychedelic-drug-guidance-paves-a-path-to-approval-while-setting-a-high-evidentiary-bar
So the regulatory machine is being tuned to strip the non-drug components out and see what the molecule does alone. Nobody has run the trial that isolates touch and neuromodulation. The fibromyalgia and phantom-limb pilots both bundled psilocybin with heavy non-drug support, and their authors call that a limitation, not a finding. The hypothesis is live and under-studied. It is not demonstrated.
One claim we will engage as argument rather than finding: that chronic pain sufferers have "demonstrated psychedelics work without psychiatric oversight." Nothing we read supports that evidentiarily. The index case was an unsupervised illegal acquisition with an n of 1.
The law, and the medication problem nobody has studied
Psilocybin is Schedule I federally with no approved product for any indication. No state program lists chronic pain as a qualifying condition. And chronic pain patients are usually on serotonergic drugs that the interaction literature barely covers.
Federal. Psilocybin and psilocyn are Schedule I under 21 CFR 1308.11, DEA codes 7437 and 7438 (https://www.govinfo.gov/content/pkg/CFR-2024-title21-vol9/xml/CFR-2024-title21-vol9-sec1308-11.xml). No psilocybin product has FDA approval for any indication. COMPASS Pathways' COMP360 — two Phase 3 trials in over 1,000 participants for treatment-resistant depression, rolling NDA with final submission expected Q4 2026 — states in its own SEC filing that launch in H1 2027 is subject to FDA approval *and* DEA rescheduling, both of which must occur before commercialization. No pain indication is mentioned. https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000059/q22026pressrelease.htm
States. Oregon (ORS 475A) runs a supported adult-use model: no medical diagnosis or practitioner referral required, and facilitators need only be 21+, hold a high school diploma, and complete roughly 128 hours of training plus a 40-hour practicum. They are not required to have medical training. Colorado's SB23-290 licenses healing centers and facilitators for adults 21+, also without a diagnosis requirement. New Mexico's 2025 Medical Psilocybin Act limits qualifying conditions to treatment-resistant depression, PTSD, substance use disorders and end-of-life care — chronic pain is not on the list. See /legal-status/oregon, /legal-status/new-mexico and /vs/oregon-vs-colorado-psilocybin-therapy.
Oregon's 2025 aggregate state data (Yu F Jr, Tafur J, Moreno F, Dahmer S, *Frontiers in Psychiatry* 2026;17:1777387) covers 5,935 clients across 5,375 sessions: behavioral adverse events at 2.42 per 1,000 sessions, medical adverse events at 2.79 per 1,000, and seven severe reactions requiring hospitalization across the year. Top stated reasons were general wellness, change of perspective, expanded consciousness, anxiety, depression and PTSD. Pain was not a prominent category. https://pmc.ncbi.nlm.nih.gov/articles/PMC13224104/
Interactions. This is where the pain population gets uniquely exposed. Halman, Kong, Sarris and Perkins' systematic review of drug–drug interactions with classic psychedelics (*Journal of Psychopharmacology* 2024;38(1):3–18) found only 52 studies across all classic psychedelics and all drug classes — few enough that case reports had to be included. https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/
What it reports: chronic lithium potentiated LSD effects with earlier onset, with seizures reported anecdotally in concurrent use; MAOI effects were mixed and unpredictable; tricyclics including desipramine, imipramine and clomipramine increased LSD's psychological effects; and for SSRIs, escitalopram pretreatment reduced the *negative* acute effects of a full psilocybin dose without blunting the positive ones (Becker AM et al., *Clinical Pharmacology & Therapeutics* 2022;111:886–895), while a retrospective survey reported weakened effects in roughly half of concurrent SSRI/SNRI users. On lithium specifically, Nayak et al. (*Pharmacopsychiatry* 2021) analysed online experience reports — not a trial — and found seizures in 47% of 62 lithium-plus-psychedelic reports versus 0 of 34 lamotrigine reports.
Chronic pain patients are frequently on duloxetine, tricyclics, tramadol and gabapentinoids simultaneously. The interaction literature for exactly that combination is thin to nonexistent. Start at /guides/psilocybin-drug-interactions and /guides/psilocybin-and-lithium, then talk to the clinician managing your prescriptions.
PsyBear takeaways
The structural complaint is fair. The evidence is not there yet. Both can be true, and conflating them is how people get hurt.
1. Watkins is right that pain is absent from the federal frame. The Federal Register notice does not mention chronic pain. EO 14401 does not mention chronic pain. New Mexico's qualifying-condition list does not include it. If you have refractory pain, the fastest-moving federal pathway was not built with you in mind.
2. That absence is not proof of suppression. It also tracks the evidence. Every human pain study we verified randomized 18 people or fewer and was labeled exploratory, feasibility or pilot by its own authors.
3. The only pain trial with an active placebo came back null. In the 2026 migraine RCT, single-dose psilocybin, a two-dose pulse and 25 mg diphenhydramine produced similar reductions in migraine frequency. That is the single most important number in this whole story, and it is the one that travels least.
4. A case report is a hypothesis, not a result. One woman, unblinded, uncontrolled, self-selected, self-dosed illegally, coming off IV ketamine ten days earlier, with a bundled protocol that makes it impossible to say what did the work. Her authors say this themselves.
5. "The touch and neuromodulation matter" is untested, not established. FDA's own final guidance concedes the psychotherapy contribution has not been characterized — and then creates incentives for sponsors to remove it. Nobody has isolated the non-drug component in a controlled pain trial. Until someone does, this is an open question being argued by people with commercial and editorial stakes on both sides.
6. Do not port the index case into your life. The patient in that report acquired and used psilocybin illegally, outside medical care, while managing a complex medication history. If you are in pain and considering this, the relevant pages are /guides/safe-trip, /guides/trip-preparation and /guides/psilocybin-drug-interactions — and a conversation with the prescriber who knows your chart.
Psilocybin and psilocyn are Schedule I under federal law. No psilocybin product is FDA-approved for any indication, including any pain condition. Oregon and Colorado license supported adult-use services within their borders only; New Mexico's medical program does not list chronic pain as a qualifying condition. This article is commentary on published literature and public documents, not medical advice. Psilocybin is contraindicated for people with personal or family histories of psychosis or bipolar disorder, and serotonergic medications — SSRIs, SNRIs, MAOIs, tricyclics — plus lithium carry documented and in some cases serious interaction risk. Talk to a clinician.
Key Takeaways
FDA's Part 15 hearing (docket FDA-2026-N-7542) was built around serious mental illness — the Federal Register notice never mentions chronic pain, and neither does Executive Order 14401. The pain evidence that advocates are pointing at is one uncontrolled single-patient case report (Jevotovsky et al., Clinical Case Reports 2024), a Phase 1 pilot in phantom limb pain with nine randomized participants, an open-label fibromyalgia pilot with five, a cluster headache RCT that missed statistical significance, and a 2026 migraine RCT where psilocybin did not separate from diphenhydramine. The strongest result in the whole field is in mice. No psilocybin pain trial anywhere is in Phase 3, and chronic pain is not a qualifying condition in New Mexico's medical program. The thesis that touch and neuromodulation matter is plausible and under-studied — but FDA's own final guidance pushes sponsors to strip non-drug components out, not to study them.
FAQ
- Did FDA ask for comment on psilocybin for chronic pain?
- No. FDA's September 14, 2026 Part 15 hearing (docket FDA-2026-N-7542) solicited comment on four topics only: provider training and credentialing, promotion of patient safety, considerations for access, and best practices for data collection and standardization. The Federal Register notice does not mention chronic pain or any non-psychiatric indication, and its cited policy background — Executive Order 14401 — names major depressive disorder, substance use disorder, serious mental illness and veteran suicide prevention.
- Is there evidence psilocybin treats chronic pain?
- Not at the level that would support a medical claim. The published human evidence is one uncontrolled single-patient case report in CRPS (Jevotovsky et al., Clinical Case Reports 2024), a Phase 1 phantom limb pain pilot with nine randomized participants, an open-label fibromyalgia pilot with five, a cluster headache RCT with 14 analyzed that did not reach statistical significance, and a 2026 migraine RCT with 18 participants in which psilocybin did not separate from diphenhydramine active placebo. No psilocybin pain trial anywhere is in Phase 3.
- What did the 2026 migraine trial find?
- Schindler, Gottschalk, Pittman and D'Souza (Headache, 2026) randomized 18 participants to single-dose psilocybin, a two-dose psilocybin pulse, or 25 mg diphenhydramine as an active placebo, and reported "similar reductions in migraine frequency" across all three. Diphenhydramine partially mimicked psilocybin's subjective effects, which complicated blinding. No serious or unexpected adverse events were reported.
- Does the mouse study prove psilocybin works for nerve pain?
- No — it is preclinical animal work. Askey et al. (Communications Biology 2026;9:707) found psilocybin reduced neuropathic pain-like behaviour in a mouse spared-nerve-injury model, that the effect was blocked by the 5-HT2A antagonist volinanserin, and that a single dose potentiated gabapentin weeks later. The authors themselves frame it as preclinical evidence warranting human investigation, not established clinical efficacy.
- Can I access legal psilocybin for chronic pain in any US state?
- No state offers psilocybin as a treatment for chronic pain. New Mexico's 2025 Medical Psilocybin Act limits qualifying conditions to treatment-resistant depression, PTSD, substance use disorders and end-of-life care. Oregon and Colorado run supported adult-use models that require no medical diagnosis at all, which also means no diagnosis-based indication for pain. Psilocybin and psilocyn remain Schedule I federally under 21 CFR 1308.11.
- What interactions should chronic pain patients worry about?
- Chronic pain patients are frequently on duloxetine, tricyclics, tramadol and gabapentinoids at once, and the interaction literature for that combination is thin to nonexistent — Halman et al.'s 2024 systematic review found only 52 studies across all classic psychedelics and all drug classes. Documented signals include lithium potentiating psychedelic effects with anecdotal seizure reports (Nayak et al. found seizures in 47% of 62 lithium-plus-psychedelic online reports), unpredictable MAOI interactions, and tricyclics increasing psychological effects. Psychiatric contraindications including psychosis and bipolar histories also apply.